Speaker: Vincent Rajkumar, MD, Hematologist, Mayo Clinic, Rochester, Minnesota. Patients with newly diagnosed multiple myeloma responded better to treatment with the oral drug combination of thalidomide (Thalomid®, Celgene) plus dexamethasone (Decadron generic, Merck) (thal/dex) than to dexamethasone therapy alone.
Speaker: Joseph J. McKendrick, MD, Director of Medical Oncology, Department of Clinical Hematology and Clinical Oncology, Box Hill Hospital, Melbourne, Victoria, Australia. Adjuvant chemotherapy with oral capecitabine (Xeloda®, Roche), an oral fluoropyrimidine preferentially activated to 5-fluorouracil (5-FU) in tumors by enzymatic action, was more cost-effective than the standard Mayo Clinic regimen of IV 5-FU and [...]
Speaker: Roger Stupp, MD, Professor of Medicine and Director, Brain Tumor and Chest Oncology Clinic, Multi-disciplinary Oncology Center, University of Lausanne Hospital, Vaudois, Lausanne, Switzerland. The addition of temozolomide (Temodar®, Schering), a chemotherapeutic agent indicated for the treatment of ana-plastic astrocytoma, to standard radiation therapy significantly improved both progression-free survival and overall survival in patients [...]
Nanoparticle Albumin-Bound Paclitaxel for Metastatic Breast Cancer Speaker: William J. Gradishar, MD, Associate Professor of Medicine; Director, Breast Oncology; and Director, Fellowship Program, Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
